Insulet Corporation (NASDAQ:PODD) is expected to report third quarter earnings results, after market close, on Wednesday 4th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.08 per share.
Looking ahead, the full year income are expected at $ 0.37 per share on the revenues of $ 874.11 million.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 217.09 million ~ $ 220.93 million
Full Year 2020 topline are forecasted in a range of$ 863.69 million ~ $ 878.46 million
Click Here For More Historical Outlooks Of Insulet Corporation
Previous Quarter Performance
Insulet Corporation revealed income for the second quarter of $ 0.22 per share, from the revenue of $ 226.30 million. The quarterly earnings extended 1,000.00 percent while revenues extended 27.75 percent compared with the same quarter last year. Wall street analysts are predicting revenue of $ 212.41 million The top line results outshined analysts by $ 13.89 million or 6.54 percent.
Stock Performance
Shares of Insulet Corporation traded up $ 7.13 or 3.30 percent on Tuesday, reaching $ 223.10 with volume of 576.30 thousand shares. Insulet Corporation has traded high as $ 227.10 and has cracked $ 217.54 on the downward trend
According to the previous trading day, closing price of $ 223.10, representing a 78.49 % increase from the 52 week low of $ 121.00 and a 15.44 % decrease over the 52 week high of $ 255.39.
The company has a market capital of $ 14.65 billion and is part of the Healthcare sector and Medical Devices industry.
Recent Analyst recommendations
- On 12th October 2020, maintained by SVB Leerink at Market Perform rating, with $ 255.00 target price.
Conference Call
Insulet Corporation will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.insulet.com
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. It sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, Israel, and internationally.
